Raab & Moskowitz Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.45M Sell
25,628
-154
-0.6% -$33.1K 1.3% 21
2026
Q1
$5.61M Sell
25,782
-600
-2% -$133K 1.25% 24
2025
Q4
$6.03M Buy
26,382
+338
+1% +$77K 1.32% 18
2025
Q3
$6.03M Sell
26,044
-166
-0.6% -$33.8K 1.35% 20
2025
Q2
$4.87M Buy
26,210
+122
+0.5% +$22.7K 1.16% 21
2025
Q1
$5.47M Sell
26,088
-214
-0.8% -$41.6K 1.37% 19
2024
Q4
$4.67M Sell
26,302
-212
-0.8% -$39K 1.15% 22
2024
Q3
$5.24M Buy
26,514
+81
+0.3% +$15.1K 1.33% 21
2024
Q2
$4.53M Sell
26,433
-196
-0.7% -$32.5K 1.23% 21
2024
Q1
$4.85M Sell
26,629
-13
-0% -$2.24K 1.36% 19
2023
Q4
$4.13M Sell
26,642
-323
-1% -$47.1K 1.3% 20
2023
Q3
$4.02M Sell
26,965
-18
-0.1% -$2.64K 1.42% 21
2023
Q2
$3.64M Sell
26,983
-467
-2% -$68.5K 1.24% 22
2023
Q1
$4.37M Sell
27,450
-507
-2% -$77.5K 1.6% 16
2022
Q4
$4.52M Sell
27,957
-71
-0.3% -$10.9K 1.72% 14
2022
Q3
$3.76M Sell
28,028
-265
-0.9% -$38K 1.58% 17
2022
Q2
$4.33M Buy
28,293
+152
+0.5% +$23.2K 1.7% 14
2022
Q1
$4.56M Buy
28,141
+20
+0.1% +$2.9K 1.56% 15
2021
Q4
$3.81M Hold
28,121
1.25% 23
2021
Q3
$3.03M Sell
28,121
-637
-2% -$72.8K 1.1% 27
2021
Q2
$3.24M Buy
28,758
+502
+2% +$56.5K 1.18% 25
2021
Q1
$3.06M Buy
28,256
+17,035
+152% +$1.82M 1.19% 25
2020
Q4
$1.2M Sell
11,221
-300
-3% -$28.8K 0.49% 64
2020
Q3
$1.01M Sell
11,521
-368
-3% -$34.6K 0.47% 63
2020
Q2
$1.17M Buy
11,889
+117
+1% +$10.3K 0.57% 53
2020
Q1
$896K Buy
11,772
+208
+2% +$17.7K 0.49% 65
2019
Q4
$1.02M Sell
11,564
-232
-2% -$19.3K 0.4% 74
2019
Q3
$893K Sell
11,796
-297
-2% -$20.4K 0.39% 77
2019
Q2
$879K Sell
12,093
-170
-1% -$13.4K 0.39% 78
2019
Q1
$988K Sell
12,263
-397
-3% -$32.5K 0.45% 72
2018
Q4
$1.17M Buy
12,660
+97
+0.8% +$8.53K 0.57% 59
2018
Q3
$1.19M Buy
12,563
+2,499
+25% +$237K 0.49% 62
2018
Q2
$932K Sell
10,064
-127
-1% -$12.4K 0.45% 68
2018
Q1
$964K Buy
10,191
+296
+3% +$32.5K 0.47% 63
2017
Q4
$956K Sell
9,895
-358
-3% -$33.7K 0.46% 67
2017
Q3
$925K Sell
10,253
-699
-6% -$53.2K 0.45% 70
2017
Q2
$771K Sell
10,952
-332
-3% -$22.3K 0.38% 76
2017
Q1
$735K Buy
11,284
+342
+3% +$21.5K 0.38% 77
2016
Q4
$685K Buy
10,942
+16
+0.1% +$977 0.37% 76
2016
Q3
$689K Sell
10,926
-988
-8% -$64K 0.39% 77
2016
Q2
$737K Sell
11,914
-252
-2% -$15.4K 0.42% 72
2016
Q1
$694K Buy
12,166
+92
+0.8% +$5.13K 0.41% 71
2015
Q4
$715K Sell
12,074
-111
-0.9% -$6.39K 0.43% 71
2015
Q3
$662K Sell
12,185
-904
-7% -$58.8K 0.43% 70
2015
Q2
$879K Hold
13,089
0.54% 63
2015
Q1
$766K Sell
13,089
-1,568
-11% -$94.7K 0.46% 70
2014
Q4
$959K Sell
14,657
-26,270
-64% -$1.66M 0.55% 56
2014
Q3
$2.36M Sell
40,927
-399
-1% -$22.2K 1.15% 24
2014
Q2
$2.33M Sell
41,326
-230
-0.6% -$12.1K 1.11% 24
2014
Q1
$1.64M Sell
41,556
-2,964
-7% -$150K 0.91% 33
2013
Q4
$1.83M Buy
+44,520
New +$2.19M 1.05% 27

Other funds holding ABBV

Raab & Moskowitz Asset Management's ABBV Position: Q2 2026 in Review

Raab & Moskowitz Asset Management reduced its AbbVie (ABBV) stake by 0.6% in Q2 2026, selling an estimated $33.1K and leaving 25,628 shares worth $6.45M. The position accounts for 1.3% of the portfolio, ranked #21.

Raab & Moskowitz Asset Management first reported a position in ABBV in Q4 2013 and has held it in 51 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Raab & Moskowitz Asset Management held 25,628 shares of AbbVie worth $6.45M as of Q2 2026.
  • Raab & Moskowitz Asset Management sold 154 AbbVie shares in Q2 2026, an estimated $33.1K.
  • AbbVie made up 1.3% of Raab & Moskowitz Asset Management's portfolio in Q2 2026, its #21 holding.
  • Raab & Moskowitz Asset Management first reported a position in AbbVie in Q4 2013 and has held it in 51 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Raab & Moskowitz Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.